[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"content-doc-dcio0f931692":3},{"user":4,"document":8,"mainDocument":27,"columnUrl":29,"subscription":30,"footer":42,"text":80},{"isAuthenticated":5,"isAdmin":5,"displayName":6,"avatarUrl":6,"nid":6,"groupLevel":7},false,"",-10,{"id":9,"fullTitle":10,"subTitle":6,"url":11,"columnId":12,"columnName":13,"columnUrl":14,"summary":6,"contentHtml":15,"mainContentHtml":6,"posterUrl":16,"createDate":17,"displayDate":18,"displayDateSlash":19,"pageviews":20,"tags":21,"hidden":5,"isSubContent":5,"replyDocOrTargetId":6,"contentType":23,"videoId":6,"liveVideoUrl":6,"useContentVideo":5,"duration":24,"price":24,"priceText":25,"priceBadgeText":25,"priceBadgeClass":26,"freeForMinGroupLevel":24,"redirectUrl":6,"readyToStream":5},"dcio0f931692","美股EYPT暴跌原因","\u002Fdoc\u002Fdcio0f931692","col18178739ee","美股资讯","\u002Fcol\u002Fcol18178739ee","\u003Cp>\n\u003C\u002Fp>\u003Cp>\u003Cspan>EyePoint Pharmaceuticals\u003Cspan>（\u003C\u002Fspan>EYPT\u003Cspan>）在今天（\u003C\u002Fspan>2026\u003Cspan>年\u003C\u002Fspan>8\u003Cspan>月\u003C\u002Fspan>17\u003Cspan>日）股价出现了约\u003C\u002Fspan> 70% \u003Cspan>的剧烈暴跌，主要原因是其\u003Cstrong>核心管线药物的\u003C\u002Fstrong>\u003C\u002Fspan>\u003Cstrong> III \u003C\u002Fstrong>\u003Cstrong>\u003Cspan>期临床试验遭遇了重大挫折\u003C\u002Fspan>\u003C\u002Fstrong>\u003Cspan>。\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan>以下是导致股价暴跌的核心事件细节：\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan>\u003Cstrong>\u003Cspan>核心原因：\u003C\u002Fspan>DURAVYU \u003C\u002Fstrong>\u003Cstrong>\u003Cspan>临床试验未达主要终点\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan>EYPT \u003Cspan>宣布，其用于治疗\u003C\u002Fspan>“\u003Cspan>湿性年龄相关性黄斑变性（\u003C\u002Fspan>wet AMD\u003Cspan>）\u003C\u002Fspan>”\u003Cspan>的核心药物\u003C\u002Fspan>\u003Cstrong>DURAVYU\u003C\u002Fstrong>\u003Cspan>，在名为\u003C\u002Fspan> LUGANO \u003Cspan>的关键\u003C\u002Fspan> III \u003Cspan>期临床试验中，\u003Cstrong>未能达到主要疗效终点\u003C\u002Fstrong>。\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cul>\n\u003Cli>\u003Cspan>\u003Cstrong>\u003Cspan>数据不达标：\u003C\u002Fspan>\u003C\u002Fstrong>\u003Cspan>此次试验的主要终点是评估患者的\u003C\u002Fspan>“\u003Cspan>最佳矫正视力（\u003C\u002Fspan>BCVA\u003Cspan>）相较于基线的变化\u003C\u002Fspan>”\u003Cspan>，并与对照组标准药物（\u003C\u002Fspan>2mg aflibercept\u003Cspan>）进行对比。在最终的完整数据集中，\u003C\u002Fspan>DURAVYU \u003Cspan>未能在此指标上达标。\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fli>\n\u003Cli>\u003Cspan>\u003Cstrong>\u003Cspan>断崖式下跌：\u003C\u002Fspan>\u003C\u002Fstrong>\u003Cspan>医药股对管线临床数据极其敏感。受此利空消息打击，\u003C\u002Fspan>EYPT \u003Cspan>股价在周一早盘遭到踩踏式抛售，暴跌超过\u003C\u002Fspan> 70%\u003Cspan>（从前一交易日的\u003C\u002Fspan> $14.75 \u003Cspan>直接砸盘至\u003C\u002Fspan> $4.06 \u003Cspan>附近），创下\u003C\u002Fspan> 52 \u003Cspan>周新低。\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fli>\n\u003C\u002Ful>\n\u003Cp>\u003Cspan>\u003Cstrong>\u003Cspan>公司的回应与辩护\u003C\u002Fspan>\u003C\u002Fstrong>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan>\u003Cspan>面对数据的失利，\u003C\u002Fspan>EyePoint \u003Cspan>官方给出了两点解释与补充：\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Col>\n\u003Cli>\u003Cspan>\u003Cstrong>\u003Cspan>数据异常干扰：\u003C\u002Fspan>\u003C\u002Fstrong>\u003Cspan>公司表示，主要终点未达标是受到了数据的\u003C\u002Fspan>“\u003Cspan>混淆（\u003C\u002Fspan>confounded\u003Cspan>）\u003C\u002Fspan>”\u003Cspan>影响。在\u003C\u002Fspan> 211 \u003Cspan>名受试患者中，有一个包含\u003C\u002Fspan> 9 \u003Cspan>名患者的不对称队列经历了\u003Cstrong>与湿性\u003C\u002Fstrong>\u003C\u002Fspan>\u003Cstrong> AMD \u003C\u002Fstrong>\u003Cstrong>\u003Cspan>无关\u003C\u002Fspan>\u003C\u002Fstrong>\u003Cspan>的视力下降，这拉低了整体的视力改善数据。\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fli>\n\u003Cli>\u003Cspan>\u003Cstrong>\u003Cspan>次要终点与安全性良好：\u003C\u002Fspan>\u003C\u002Fstrong>\u003Cspan>尽管错失了主要目标，公司强调\u003C\u002Fspan> DURAVYU \u003Cspan>依然满足了多项次要终点指标，且整体安全性和耐受性良好。在白内障、眼压异常或眼部炎症等不良反应方面，与对照组没有实质性差异。\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fli>\n\u003C\u002Fol>\n\u003Cp>\u003Cspan>━━━━━━━━━━━━━━━━━━━━━━\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan>【原创声明】\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan>\u003Cspan>本文由美股投资网（\u003C\u002Fspan>TradesMax.com\u003Cspan>）研究团队原创完成。\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan>原创机构：美股投资网\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan>\u003Cspan>英文品牌：\u003C\u002Fspan>TradesMax\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan>\u003Cspan>本文基于公开财报、\u003C\u002Fspan>SEC\u003Cspan>文件、市场数据、机构资金、期权交易及产业链信息进行独立分析\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan>如需引用本文，请注明：\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan>\u003Cspan>“美股投资网（\u003C\u002Fspan>TradesMax.com\u003Cspan>）原创研究”。\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan>━━━━━━━━━━━━━━━━━━━━━━\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003C\u002Fp>","https:\u002F\u002Fwww.tradesmax.com\u002Fimages\u002Fa_Stock\u002FE\u002FEYPT\u002FEYPT.jpg","2026-08-17T15:32:25","2026.08.17","2026\u002F08\u002F17",56723,[22],"EYPT","Article",0,"免费","success",{"id":9,"fullTitle":10,"subTitle":6,"url":11,"columnId":12,"columnName":13,"columnUrl":14,"summary":6,"contentHtml":15,"mainContentHtml":6,"posterUrl":16,"createDate":17,"displayDate":18,"displayDateSlash":19,"pageviews":20,"tags":28,"hidden":5,"isSubContent":5,"replyDocOrTargetId":6,"contentType":23,"videoId":6,"liveVideoUrl":6,"useContentVideo":5,"duration":24,"price":24,"priceText":25,"priceBadgeText":25,"priceBadgeClass":26,"freeForMinGroupLevel":24,"redirectUrl":6,"readyToStream":5},[22],"\u002Fcol\u002Fstocknews",{"visible":5,"marketingHtml":31,"services":32,"recentDocuments":41},"\u003Cfigure class=\"image\">\u003Ca href=\"https:\u002F\u002Fstockwe.com\u002Fdoc\u002Fdcio537efad5\" rel=\"noopener noreferrer\">\u003Cimg src=\"\u002Fimg\u002Fstockwewebfiles\u002Fweb-202408-stk\u002F1586109431mceclip0.jpg\">\u003C\u002Fa>\u003C\u002Ffigure>\u003Cdiv class=\"text-center\">\u003Ch2 class=\"card-title mx-auto\">\u003Cbr>\u003Ca rel=\"noopener noreferrer\" href=\"https:\u002F\u002Fstockwe.com\u002Fdoc\u002Fdcio537efad5\">案例介绍：英伟达深度研究报告\u003C\u002Fa>\u003C\u002Fh2>\u003C\u002Fdiv>",[33,37],{"productId":34,"serviceName":35,"priceText":36},"prod_PPxdDdK87QaiLv","月付","$12.95美元",{"productId":38,"serviceName":39,"priceText":40},"prod_PPxeMs3bix1da5","年付","$149.00美元",[],{"links":43,"images":71,"summaryHtml":76,"aboutTitle":77,"aboutHtml":78,"copyrightHtml":79},[44,47,50,53,56,59,62,65,68],{"label":45,"url":46},"深度报告","\u002Fcol\u002FdepthReport",{"label":48,"url":49},"VIP会员","\u002Fvip",{"label":51,"url":52},"期权推荐","\u002FOption",{"label":54,"url":55},"低价暴涨股","\u002FPenny",{"label":57,"url":58},"AI智能体","\u002FAiAgent",{"label":60,"url":61},"常见问题","https:\u002F\u002Fstockwe.com\u002FFAQ",{"label":63,"url":64},"美股课程","\u002Fcol\u002Fvideos",{"label":66,"url":67},"免责声明","\u002Fdisclaimer",{"label":69,"url":70},"联系我们","\u002FContactUs",[72,73,74,75],"\u002Fimg\u002Fstockwebsiteblob\u002Fweb-202509-stk\u002FUploaderzic2tuwsol2_2025_09_11_18_21_07.gif","\u002Fimg\u002Fstockwebsiteblob\u002Fweb-202509-stk\u002FUploadercakzdvydksw_2025_09_03_09_00_56.png","\u002Fimg\u002Fstockwebsiteblob\u002Fweb-202509-stk\u002FUploadergtjyagwvoyk_2025_09_14_08_32_05.png","\u002Fimg\u002Fstockwebsiteblob\u002Fweb-202509-stk\u002FUploader3u0tt4jhlqh_2025_09_23_22_30_48.png","邮箱: buy@TradesMax.com 美国电话 626-378-3637","公司介绍","\u003Cp class=\"MsoNormal\">美股大数据 \u003Ca href=\"https:\u002F\u002Fstockwe.com\" rel=\"noopener\">StockWe.com\u003C\u002Fa> 是一个美国领先的金融和美股信息大数据提供商，紧盯华尔街金融市场和行情，2008年成立于美国硅谷，创始人是前纽约证券交易所资深分析师Ken，联合多位摩根斯坦利分析师，谷歌 Meta工程师利用AI和大数据，配合十多年美股实战经验和业内量化交易模型，每天处理海量股票数据：挖掘潜力大牛股，捕捉期权异动大单，实时主力资金流向、机构持仓变化、川普突发新闻，美股买卖信号第一时间发到您手机APP。\u003C\u002Fp>","专业美股投资者都在这里",{"loading":81,"search":82,"searchPlaceholder":82,"hotContent":83,"draft":84,"noData":85,"searchNoData":86,"courseContent":87,"more":88,"buyNow":89,"subscribeNow":90,"encoding":91,"paidContent":92},"Loading...","搜索","热门内容","草稿","目前没有任何内容公布","当前检索内容没有数据","课程内容","更多","立即购买后观看","- 立即订阅 -","视频编码中...","付费内容"]